Journal of Drug Metabolism & Toxicology
Open Access

Derek S Larson

Publications

• Research Article
  Pharmacokinetics of Iron Isomaltoside1000 in Patients with Stage 5 Chronic Kidney Disease on Dialysis Therapy
  Author(s): Diptesh R Gupta, Derek S Larson, Lars L Thomsen and Daniel W Coyne Diptesh R Gupta, Derek S Larson, Lars L Thomsen and Daniel W Coyne
  
  Background: Iron deficiency anemia is common in patients with chronic kidney disease, and intravenous iron is the preferred treatment for those on dialysis. We investigated the pharmacokinetics, pharmacodynamics, and safety of three doses (100 mg, 200 mg, and 500 mg) of iron isomaltoside 1000administered as bolus injections in patients with stage 5 chronic kidney disease on dialysis therapy. Methods: This prospective, randomized, open-label pharmacokinetic study was conducted in 18 patients at one center. Patients were randomly assigned in a 1:1:1 ratio to receive a single dose of 100 mg, 200 mg, or 500 mg intravenous bolus injection (6 patients each) of iron isomaltoside 1000 at baseline visit. The pharmacokinetic, pharmacodynamics, and safety parameters were assessed over seven days and increases in serum-iron was used as a surrogate for iron isomaltoside 1000. Results: There was a d.. View More»
  DOI: 10.4172/2157-7609.1000152

  Abstract PDF

Relevant Topics